Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2657655 | 0.98 | HTR2C (0.40) | HTR2CHTR2BHTR2ACD44CHRNB2 | |
| SCHEMBL798791 | 0.83 | CD44 (0.56) | HTR2CHTR2BHTR2ACD44PNMT | |
| SCHEMBL30218840 | 0.83 | CD44 (0.56) | HTR2CHTR2BHTR2ACD44PNMT | |
| SCHEMBL329629 | 0.83 | PNMT (0.56) | HTR2CHTR2BHTR2ACD44PNMT | |
| Hydrochloric Acid SCHEMBL2259424 | 0.82 | PNMT (0.54) | HTR2CHTR2BHTR2ACD44PNMT | |
| Hydrochloric Acid SCHEMBL2260124 | 0.82 | CD44 (0.54) | HTR2CHTR2BHTR2ACD44PNMT | |
| SCHEMBL11337766 | 0.80 | PNMT (0.46) | HTR2CHTR2BHTR2ACD44PNMT | |
| SCHEMBL16559767 | 0.80 | CA2 (0.40) | CD44PNMTKIF11 | |
| SCHEMBL11622743 | 0.79 | PRCP (0.34) | CD44PNMTASIC3 | |
| SCHEMBL11443442 | 0.74 | HTR2A (0.43) | HTR2CHTR2BHTR2AASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| CN-117964544-A | Synthetic method of isoindoline derivatives | 上海吉奉生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230079990-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| CN-114364667-A | 3-substituted piperidines for Cbl-b inhibition and the use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-5726197-A | ADRENORECEPTORS AND ADMINISTERING | SYNTEX (U.S.A.) INC. (US) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | HTR2C 3932/4885HTR2B 3155/4885HTR2A 4358/4885 |
| US-20230079990-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | HTR2C 3932/4885HTR2B 3155/4885HTR2A 4358/4885 |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | HTR2C 4123/4885HTR2B 4128/4885HTR2A 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.